These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 17559757)

  • 1. Patient acceptance of a novel electronic auto-injector device to administer recombinant human growth hormone: results from an open-label, user survey of everyday use.
    Dahlgren J; Veimo D; Johansson L; Bech I
    Curr Med Res Opin; 2007 Jul; 23(7):1649-55. PubMed ID: 17559757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. User trial of Easypod, an electronic autoinjector for growth hormone.
    Tauber M; Payen C; Cartault A; Jouret B; Edouard T; Roger D
    Ann Endocrinol (Paris); 2008 Dec; 69(6):511-6. PubMed ID: 18589398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Children and adolescent acceptability of a new device system to administer human growth hormone--a pilot study.
    Kappelgaard AM; Mikkelsen S; Bagger C; Fuchs GS
    J Pediatr Endocrinol Metab; 2012; 25(3-4):285-94. PubMed ID: 22768658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient Acceptance, Ease of Use, and Preference for Norditropin NordiFlex with NordiFlex PenMate: Results from an Open-Label, User Survey of Everyday Use.
    Hokken-Koelega A; Keller A; Rakov V; Kipper S; Dahlgren J
    ISRN Endocrinol; 2011; 2011():803948. PubMed ID: 22363887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ease of use and acceptability of a new pen device for the administration of growth hormone therapy in pediatric patients: an open-label, uncontrolled usability test.
    Fuchs GS; Mikkelsen S; Knudsen TK; Kappelgaard AM
    Clin Ther; 2009 Dec; 31(12):2906-14. PubMed ID: 20110030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement of treatment adherence with growth hormone by easypod™ device: experience of an Italian centre.
    Maggio MC; Vergara B; Porcelli P; Corsello G
    Ital J Pediatr; 2018 Sep; 44(1):113. PubMed ID: 30261918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ease of use and preference for a new disposable self-injection pen compared with a reusable pen for administering recombinant human growth hormone: A multicenter, 2-month, single-arm, open-label clinical trial in patient-caregiver dyads.
    Hey-Hadavi J; Pleil A; Deeb LC; Fuqua JS; Silverman LA; Reiner B; Newfield R; Rajicic N; Wajnrajch MP; Cara JF
    Clin Ther; 2010 Nov; 32(12):2036-47. PubMed ID: 21118739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Norditropin SimpleXx: a liquid human growth hormone formulation, a pen system and an auto-insertion device.
    Müller J; Skakkebaek NE; Jacobsen BB; Keller E; Heinrich U; Hartmann K; Hokken-Koelega AC; Delemarre van de Waal HA
    Horm Res; 1999; 51 Suppl 3():109-12. PubMed ID: 10592453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of recombinant human growth hormone administered by cool.click 2, a new needle-free device, compared with subcutaneous administration using a conventional syringe and needle.
    Brearley C; Priestley A; Leighton-Scott J; Christen M
    BMC Clin Pharmacol; 2007 Oct; 7():10. PubMed ID: 17922895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Facilitating and understanding the family's choice of injection device for growth hormone therapy by using conjoint analysis.
    Ahmed SF; Smith WA; Blamires C
    Arch Dis Child; 2008 Feb; 93(2):110-4. PubMed ID: 17412745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment adherence with the easypod™ growth hormone electronic auto-injector and patient acceptance: survey results from 824 children and their parents.
    Bozzola M; Colle M; Halldin-Stenlid M; Larroque S; Zignani M;
    BMC Endocr Disord; 2011 Feb; 11():4. PubMed ID: 21294891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimum method for administration of biosynthetic human growth hormone: a randomised crossover trial of an Auto Injector and a pen injection system.
    Stanhope R; Albanese A; Moyle L; Hamill G
    Arch Dis Child; 1992 Aug; 67(8):994-7. PubMed ID: 1520018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding and meeting the needs of those using growth hormone injection devices.
    Dumas H; Panayiotopoulos P; Parker D; Pongpairochana V
    BMC Endocr Disord; 2006 Oct; 6():5. PubMed ID: 17034628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are needle-free injections a useful alternative for growth hormone therapy in children? Safety and pharmacokinetics of growth hormone delivered by a new needle-free injection device compared to a fine gauge needle.
    Dörr HG; Zabransky S; Keller E; Otten BJ; Partsch CJ; Nyman L; Gillespie BK; Lester NR; Wilson AM; Hyrén C; van Kuijck MA; Schuld P; Schoenfeld SL
    J Pediatr Endocrinol Metab; 2003 Mar; 16(3):383-92. PubMed ID: 12705363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient preference for a new growth hormone injection device: results of an open-label study in Japanese pediatric patients.
    Kappelgaard AM; Mikkelsen S; Knudsen TK; Fuchs GS
    J Pediatr Endocrinol Metab; 2011; 24(7-8):489-96. PubMed ID: 21932587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integration of nurse-led virtual reviews with growth hormone device-linked patient adherence information: a mixed methods feasibility study.
    Stokes H; Jones J; Worth C; Nicholson J; Fullwood C; Banerjee I
    Front Endocrinol (Lausanne); 2023; 14():1167854. PubMed ID: 37324260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adherence in children with growth hormone deficiency treated with r-hGH and the easypod™ device.
    Loche S; Salerno M; Garofalo P; Cardinale GM; Licenziati MR; Citro G; Caruso Nicoletti M; Cappa M; Longobardi S; Maghnie M; Perrone R
    J Endocrinol Invest; 2016 Dec; 39(12):1419-1424. PubMed ID: 27406716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of user-friendliness of the Norditropin FlexPro for pediatric patients treated with recombinant human growth hormone: results of an open-label user survey.
    Adachi M
    J Pediatr Endocrinol Metab; 2013; 26(11-12):1105-10. PubMed ID: 23843576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An open-label trial of a sumatriptan auto-injector for migraine in patients currently treated with subcutaneous sumatriptan.
    Landy SH; Tepper SJ; Wein T; Schweizer E; Ramos E
    Headache; 2013 Jan; 53(1):118-125. PubMed ID: 23148799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psychological responses to the needle-free Medi-Jector or the multidose Disetronic injection pen in human growth hormone therapy.
    Verrips GH; Hirasing RA; Fekkes M; Vogels T; Verloove-Vanhorick SP; Delemarre-Van de Waal HA
    Acta Paediatr; 1998 Feb; 87(2):154-8. PubMed ID: 9512200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.